Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. Up to 3 control patients without a history of cancer and matched with each case for center, sex, age at MPN diagnosis, date of diagnosis, and MPN disease duration were included (n = 1234). Cases were comparable to controls for MPN type, driver mutations and cardiovascular risk factors. The frequency of thrombosis preceding MPN was similar for cases and controls (P = .462). Thrombotic events after MPN and before second cancer were higher in cases than in controls (11.6% vs 8.1%; P = .013), because of a higher proportion of arterial thromboses (6.2% vs 3.7%; P = .015). After adjustment for confounders, the occurrence of arterial thrombosis remained independently associated with the risk of carcinoma (odds ratio, 1.97; 95% confidence interval, 1.14-3.41), suggesting that MPN patients experiencing arterial events after MPN diagnosis deserve careful clinical surveillance for early detection of carcinoma. This study was registered at www.clinicaltrials.gov as NCT03745378.

Azienda Ospedaliero Universitaria Maggiore della Carità Novara Italy

Center of Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliera Universitaria Careggi Florence Italy

Department of Experimental and Clinical Medicine University of Florence Florence Italy

Department of Hemato oncology University Hospital Olomouc Olomouc Czech Republic

Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo Pavia Pavia Italy

Department of Molecular Medicine University of Pavia Pavia Italy

Department of Oncology Hematology Hemostaseology and Stem Cell Transplantation University Hospital Rheinisch Westfälische Technische Hochschule Aachen Aachen Germany

Division of Hematology Department of Translational Medicine University of Eastern Piedmont Novara Italy

Ematology Unit Azienda Ospedaliera Santa Croce e Carle Cuneo Italy

Fondazione Policlinico Universitario A Gemelli Istituti di Ricovero e Cura a Carattere Scientifico Rome Italy

FROM Research Foundation Papa Giovanni XXIII Hospital Bergamo Italy

Guy's and St Thomas' National Health Service Foundation Trust London United Kingdom

Haemostasis Unit Department of Clinical and Experimental Medicine Policlinico Vittorio Emanuele Hospital University of Catania Catania Italy

Hematology and Bone Marrow Transplantation Unit IRCCS San Raffaele Scientific Institute Milan Italy

Hematology Department Hospital Clinic Barcelona Spain

Hematology Department Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela Spain

Hematology Department Hospital Clínico Universitario Valencia Spain

Hematology Department Hospital del Mar Barcelona Spain

Hematology Department Hospital Universitario Miguel Servet Zaragoza Spain

Hematology Department Hospital Universitario Vall d'Hebron Barcelona Spain

Hematology Division Città della Salute e della Scienza Hospital Torino Italy

Hematology Division Foundation Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico University of Milan Milan Italy

Hematology Division Ospedale San Gerardo Azienda Socio Sanitaria Territoriale Monza Italy

Hematology Division Papa Giovanni XXIII Hospital Bergamo Italy

Hematology Division San Bortolo Hospital Vicenza Italy

Hematology Institute and Blood Bank Meir Medical Center Kfar Saba Israel

Hematology Unit Azienda Unità Sanitaria Locale IRCCS di Reggio Reggio Emilia Italy

Institute of Hematology Catholic University Rome Italy

Institute of Hematology L and A Seràgnoli S Orsola Malpighi Hospital Bologna Italy

Oncology Unit Cardinal Massaia Hospital Asti Italy; and

Queen's University Belfast United Kingdom

Rete Laziale Myeloproliferative Neoplasm Rome Italy

Sackler School of Medicine Tel Aviv University Tel Aviv Israel

Section of Hematology Department of Medicine University of Verona Verona Italy

Unit of Hematology Department of Oncology University of Torino Torino Italy

University Clinic for Hematology and Oncology Minden University of Bochum Bochum Germany

Blood. 2020 Jan 30;135(5):301-302. doi: 10.1182/blood.2019004627. PubMed

Citace poskytuje Crossref.org

Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03745378